New York State Teachers Retirement System Has $6.98 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

New York State Teachers Retirement System grew its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,138 shares of the biotechnology company's stock after buying an additional 4,057 shares during the quarter. New York State Teachers Retirement System owned approximately 0.06% of BioMarin Pharmaceutical worth $6,976,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Primecap Management Co. CA boosted its holdings in shares of BioMarin Pharmaceutical by 0.4% during the third quarter. Primecap Management Co. CA now owns 18,867,435 shares of the biotechnology company's stock worth $1,326,192,000 after purchasing an additional 77,350 shares during the period. Geode Capital Management LLC boosted its holdings in shares of BioMarin Pharmaceutical by 1.9% during the third quarter. Geode Capital Management LLC now owns 3,260,050 shares of the biotechnology company's stock worth $228,632,000 after purchasing an additional 60,692 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of BioMarin Pharmaceutical by 4.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,401,628 shares of the biotechnology company's stock worth $98,520,000 after purchasing an additional 55,699 shares during the period. abrdn plc boosted its holdings in shares of BioMarin Pharmaceutical by 31.9% during the fourth quarter. abrdn plc now owns 695,802 shares of the biotechnology company's stock worth $45,735,000 after purchasing an additional 168,121 shares during the period. Finally, Erste Asset Management GmbH bought a new position in BioMarin Pharmaceutical during the third quarter valued at approximately $48,527,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Trading Down 0.5 %

Shares of BMRN stock traded down $0.33 on Friday, reaching $68.40. The company had a trading volume of 1,065,742 shares, compared to its average volume of 1,574,473. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The stock has a market cap of $13.04 billion, a PE ratio of 31.00, a PEG ratio of 0.58 and a beta of 0.28. The company has a 50-day moving average of $64.84 and a 200-day moving average of $71.05. BioMarin Pharmaceutical Inc. has a 12 month low of $60.63 and a 12 month high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 10.10% and a net margin of 14.96%. On average, equities analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

Analysts Set New Price Targets

BMRN has been the topic of several recent research reports. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday. JPMorgan Chase & Co. cut their price objective on shares of BioMarin Pharmaceutical from $110.00 to $109.00 and set an "overweight" rating on the stock in a research report on Wednesday, October 30th. Piper Sandler lifted their price target on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a research report on Thursday. Bank of America lifted their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Thursday. Finally, Robert W. Baird dropped their price target on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $93.81.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.